
March 3 (Reuters) - Takeda Pharmaceutical 4502.T:
PROTAGONIST AND TAKEDA ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE IN PATIENTS WITH POLYCYTHEMIA VERA
PROTAGONIST THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT WITH HIGHER CLINICAL RESPONDERS ON RUSFERTIDE
PROTAGONIST THERAPEUTICS INC - ALL FOUR KEY SECONDARY ENDPOINTS MET IN VERIFY STUDY
PROTAGONIST THERAPEUTICS INC - RUSFERTIDE GENERALLY WELL TOLERATED WITH NO NEW SAFETY FINDINGS
PROTAGONIST THERAPEUTICS INC - IMPACT ON TAKEDA'S FY2024 FINANCIAL RESULTS IS IMMATERIAL
Source text: ID:nBwbPzjCsa
Further company coverage: 4502.T